Janux Therapeutics, Inc.
NASDAQ:JANXBiotechnology
-$0.25 today
- Market cap
- $629.58M
- Beta
- 2.52
- P/E (TTM)
- -7.6
- EPS (TTM)
- -$1.83
Volume 0.65M
Average 1.02M
Returns on capital
Janux Therapeutics, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-11.9%
avg 5.1%
ROIC
-16.0%
avg -1051.8%
ROA
-11.3%
avg -103.6%
Analysis
ROA is currently the strongest return metric at -11.3% versus its period average of -103.6%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
David Alan Campbell | President, Co-Founder, CEO & Director | USD 1.05M | 66 | 264.74K | 0.43% |
Thomas Diraimondo | Chief Scientific Officer | USD 653.9K | 40 | 109.90K | 0.18% |
Charles Winter | Chief Technical Officer | USD 590.4K | 57 | — | — |
Janeen Doyle | Chief Corporate & Business Development Officer | USD 549.03K | 48 | — | — |
James Pennington | General Counsel & Corporate Secretary | — | — | — | — |
Matt Whitmire | Vice President of Finance | — | — | — | — |
Mandie Forman-Sklansky | Head of Human Resources | — | — | — | — |
Maria Dobek | Vice President of Accounting | — | 36 | 32.27K | 0.05% |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Jul 31, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
10
$457,074.36
Net Transaction Value
−$457,074.36
Net selling
Most Active
Meyer Andrew Hollman
3 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Jun 2, 26Jun 2, 2026 | Doyle Janeen Noel Direct | Sell | $56.9K$56,943.71 |
| May 11, 26May 11, 2026 | Dobek Maria Direct | Sell | $28.9K$28,878.46 |
| Jan 2, 26Jan 2, 2026 | Meyer Andrew Hollman Direct | Sell | $25.8K$25,798.67 |
| Jan 2, 26Jan 2, 2026 | DiRaimondo Thomas Direct | Sell | $34.4K$34,393.65 |
| Jan 2, 26Jan 2, 2026 | Campbell David Alan Direct | Sell | $110.8K$110,828.56 |
| Jan 2, 26Jan 2, 2026 | Winter Charles M. Direct | Sell | $33K$32,965.73 |
| Jan 2, 26Jan 2, 2026 | McIver Zachariah Direct | Sell | $37.3K$37,263.22 |
| Jan 2, 26Jan 2, 2026 | Dobek Maria Direct | Sell | $20.1K$20,073.26 |
| Dec 1, 25Dec 1, 2025 | Meyer Andrew Hollman Direct | Sell | $88.7K$88,707.96 |
| Dec 1, 25Dec 1, 2025 | Meyer Andrew Hollman Direct | Sell | $21.2K$21,221.14 |
Summary
Insiders reported 0 buys worth $0.00 and 10 sells worth $457,074.36 over the last 12 months. That adds up to net selling of $457,074.36. Meyer Andrew Hollman was the most active insider with 3 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A5 analysts |
| Revenue | N/A | N/A | +5.1% | +61.4% (5yr)6 analysts |
| Net Income | N/A | N/A | N/A | N/A6 analysts |
| EBIT | N/A | N/A | N/A | N/A6 analysts |
Analysis
Recent growth has been strongest in Revenue at +5.1% over three years. Forward estimates point to Revenue at +61.4% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Who does Janux Therapeutics, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Questions
Management questions
Common questions about JANX's management, answered from reported figures.
Who manages JANX?
Janux Therapeutics, Inc. (JANX) lists 8 active executives. The top listed executive is Charles Winter, Chief Technical Officer.
Are JANX insiders buying or selling?
Recent insider activity shows net buying of $35.94M.
Continue the stock analysis
Jump to another research area for this company.